Galmed Pharmaceuticals Ltd.
GLMD
$1.21
-$0.03-2.26%
NASDAQ
| 06/30/2025 | 03/31/2025 | 06/30/2024 | 06/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -126.00% | 65.60% | 12.24% | 12.24% | 12.24% |
| Total Depreciation and Amortization | -- | -- | 722.22% | 722.22% | 722.22% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 667.95% | -95.73% | -22.08% | -22.08% | -22.08% |
| Change in Net Operating Assets | 545.39% | 75.98% | 87.19% | 87.19% | 87.19% |
| Cash from Operations | -8.65% | 40.73% | 44.43% | 44.43% | 44.43% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -1,877.92% | 93.49% | 222.22% | 222.22% | 222.22% |
| Cash from Investing | -1,877.92% | 93.49% | 222.22% | 222.22% | 222.22% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 298.61% | 237.95% | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 298.61% | 237.95% | -- | -- | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 70.69% | 102.29% | 126.82% | 126.82% | 126.82% |